2-哌嗪-1-基烟碱 | 87394-64-7

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-哌嗪-1-基烟碱
• 中文别名: 2-(1-哌嗪基)烟酰胺；2-哌嗪-1-基烟酰胺
• 英文名称: 2-(piperazin-1-yl)pyridine-3-carboxamide
• 英文别名: 2-(piperazin-1-yl)nicotinamide；2-Piperazin-1-ylnicotinamide；2-piperazin-1-ylpyridine-3-carboxamide
• CAS: 87394-64-7
• 化学式: C₁₀H₁₄N₄O
• mdl: MFCD08061093
• 分子量: 206.247
• InChiKey: RYNARQDUUQTTFJ-UHFFFAOYSA-N

物化性质

• 稳定性/保质期：
  按规定使用和贮存的情况下，这些物质不会分解，并且能够避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  71.2
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933599090

反应信息

• 作为产物：
  描述：

  2-哌嗪烟酰腈 在 硫酸 作用下， 反应 19.0h， 以47%的产率得到2-哌嗪-1-基烟碱
  参考文献：
  名称：

  PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF

  摘要：

  本发明提供了化合物、其组合物以及使用它们的方法。

  公开号：

  US20180127370A1

文献信息

• Substituted Nicotinamide Compounds
  申请人：Hamblett Christopher

  公开号：US20090105264A1

  公开（公告）日：2009-04-23

  The present invention relates to a novel class of substituted nicotinamides. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.

  本发明涉及一类新型的替代烟酰胺化合物。这些化合物可以抑制组蛋白去乙酰化酶，适用于选择性诱导终末分化，并阻止肿瘤细胞的生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物在治疗具有以肿瘤细胞增殖为特征的患者方面是有用的。本发明的化合物还可能在预防和治疗TRX介导的疾病方面有用，如自身免疫、过敏和炎症性疾病，以及预防和/或治疗中枢神经系统（CNS）疾病，如神经退行性疾病。本发明还提供了包含本发明化合物的药物组合物，以及这些药物组合物的安全用药方案，易于遵循，并在体内产生这些化合物的治疗有效量。
• 2-ALKOXY-5,6,7,8-TETRAHYDROQUINOXALINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0668276A1

  公开（公告）日：1995-08-23

  A compound represented by general formula (1) or a nontoxic salt thereof, a process for producing the same, and a remedy for diseases related to the serotoninergic neuron system containing the same as the active ingredient, wherein R1 represents hydrogen or lower alkyl; R2 represents pyridyl which may be substituted by 1-3 halogen atoms, lower alkyl, trifluoromethyl, lower alkoxy, carbamoyl or cyano groups, or pyrimidinyl which may be substituted by 1-2 lower alkyl or lower alkoxy groups; and n represents an integer of 2 to 5. The compound (1) and nontoxic salts thereof show a strong affinity for serotonin 1A receptors and are useful as remedies for diseases related to the serotoninergic neuron system, such as a motion sickness remedy, space sickness remedy, antiemetic, vertigo remedy, antidepressant, anxiolytic, and ameliorant for eating disorder.

  一种通式(1)代表的化合物或其无毒盐，一种生产该化合物或其无毒盐的工艺，以及一种含有该化合物或其无毒盐作为活性成分的治疗与血清素能神经元系统有关的疾病的药物，其中R1代表氢或低级烷基；R2代表可被1-3个卤素原子、低级烷基、三氟甲基、低级烷氧基、氨基甲酰基或氰基取代的吡啶基，或可被1-2个低级烷基或低级烷氧基取代的嘧啶基；n代表2-5的整数。化合物(1)及其无毒盐对血清素 1A 受体有很强的亲和力，可用于治疗与血清素能神经元系统有关的疾病，如晕车药、晕船药、止吐药、眩晕药、抗抑郁药、抗焦虑药和改善饮食失调的药物。
• Phenyl amino piperidine mTORC inhibitors and uses thereof
  申请人：Navitor Pharmaceuticals, Inc.

  公开号：US10414727B2

  公开（公告）日：2019-09-17

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• Pyridinylpiperazines, a new class of selective .alpha.2-adrenoceptor antagonists
  作者：Walfred S. Saari、Wasyl Halczenko、Stella W. King、Joel R. Huff、James P. Guare、Cecilia A. Hunt、William C. Randall、Paul S. Anderson、Victor J. Lotti

  DOI：10.1021/jm00366a007

  日期：1983.12

  A series of 1-(2-pyridinyl)piperazine derivatives was synthesized and evaluated for adrenergic activity. In vitro activity was assessed through the antagonism of clonidine's effect in the rat, isolated, field-stimulated vas deferens and by the displacement of [3H]clonidine from membrane binding sites of calf cerebral cortex. Antagonism of clonidine-induced mydriasis in the rat was used as an in vivo assay. Several members of the series proved to be potent, selective alpha 2-adrenoceptor antagonists. 1-(3-Fluoro-2-pyridinyl)piperazine was more potent than either yohimbine or rauwolscine in displacement of [3H]clonidine and had a higher affinity for this binding site (alpha 2) than for the [3H]prazosin site (alpha 1). In vivo, the 3-F derivative was more potent than the reference standards in reversing clonidine-induced mydriasis. None of the members of this series was more selective or potent than rauwolscine in antagonizing clonidine in the rat vas deferens.
• LACTAMS AS TACHYKININ ANTAGONISTS
  申请人：Pfizer Limited

  公开号：EP1456200A1

  公开（公告）日：2004-09-15